ENT Disorder Treatment Market by Indication and Geography - Forecast and Analysis 2021-2025

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 01: Parent market

• 2.2 Market characteristics
  • Exhibit 02: Market characteristics

• 2.3 COVID-19 impact on healthcare sector

• 2.4 Value chain analysis
  • Exhibit 03: Value chain analysis: Pharmaceuticals

3 Market Sizing

• 3.1 Market definition
  • Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020-2025
  • Exhibit 06: Global - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 07: Global market: Year-over-year growth 2020-2025 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
  • Exhibit 08: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers
  • Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers
  • Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants
  • Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes
  • Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry
  • Exhibit 13: Threat of rivalry

• 4.7 Market condition
  • Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Indication

• 5.1 Market segments

• 5.2 Comparison by Indication

• 5.3 Rhinitis - Market size and forecast 2020-2025
  • Exhibit 17: Rhinitis - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 19: Rhinitis - Year-over-year growth 2020-2025 (%)

• 5.4 Sinusitis - Market size and forecast 2020-2025
  • Exhibit 20: Sinusitis - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 21: Classification of sinusitis
  • Exhibit 22: Sinusitis - Year-over-year growth 2020-2025 (%)

• 5.5 Otitis media - Market size and forecast 2020-2025
  • Exhibit 23: Otitis media - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 24: Otitis media - Year-over-year growth 2020-2025 (%)

• 5.6 Tonsillitis - Market size and forecast 2020-2025
  • Exhibit 25: Tonsillitis - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 26: Tonsillitis - Year-over-year growth 2020-2025 (%)

• 5.7 Market opportunity by Indication
  • Exhibit 27: Market opportunity by Indication

6 Customer Landscape

7 Geographic Landscape

• 7.1 Geographic segmentation
  • Exhibit 29: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison
  • Exhibit 30: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
  • Exhibit 31: North America - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 32: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
  • Exhibit 33: Europe - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 34: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
  • Exhibit 35: Asia - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 36: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
  • Exhibit 37: ROW - Market size and forecast 2020-2025 ($ billion)
  • Exhibit 38: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries
  • Exhibit 39: Key leading countries

• 7.8 Market opportunity by geography
  • Exhibit 40: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges
  • Exhibit 42: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
  • Exhibit 43: Vendor landscape

• 9.3 Landscape disruption
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered
  • Exhibit 46: Vendors covered

• 10.2 Market positioning of vendors
  • Exhibit 47: Market positioning of vendors

• 10.3 AbbVie Inc.
  • Exhibit 48: AbbVie Inc. - Overview
  • Exhibit 49: AbbVie Inc. - Business segments
  • Exhibit 50:AbbVie Inc.- Key news
  • Exhibit 51: AbbVie Inc. - Key offerings

• 10.4 ALK-Abello AS
  • Exhibit 52: ALK-Abello AS - Overview
  • Exhibit 53: ALK-Abello AS - Product and service
  • Exhibit 54: ALK-Abello AS - Key offerings

• 10.5 Bayer AG
  • Exhibit 55: Bayer AG - Overview
  • Exhibit 56: Bayer AG - Business segments
  • Exhibit 57: Bayer AG - Key news
  • Exhibit 58: Bayer AG - Key offerings
  • Exhibit 59: Bayer AG - Segment focus

• 10.6 Covis Pharma BV
  • Exhibit 60: Covis Pharma BV - Overview
  • Exhibit 61: Covis Pharma BV - Product and service
  • Exhibit 62: Covis Pharma BV - Key offerings

• 10.7 F. Hoffmann-La Roche Ltd.
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Overview
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 65: F. Hoffmann-La Roche Ltd.- Key news
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus

• 10.8 GlaxoSmithKline Plc
  • Exhibit 68: GlaxoSmithKline Plc - Overview
  • Exhibit 69: GlaxoSmithKline Plc - Business segments
  • Exhibit 70: GlaxoSmithKline Plc- Key news
  • Exhibit 71: GlaxoSmithKline Plc - Key offerings
  • Exhibit 72: GlaxoSmithKline Plc - Segment focus

• 10.9 Johnson & Johnson
  • Exhibit 73: Johnson & Johnson - Overview
  • Exhibit 74: Johnson & Johnson - Business segments
  • Exhibit 75: Johnson & Johnson- Key news
  • Exhibit 76: Johnson & Johnson - Key offerings
  • Exhibit 77: Johnson & Johnson - Segment focus

• 10.10 Merck & Co. Inc.
  • Exhibit 78: Merck & Co. Inc. - Overview
  • Exhibit 79: Merck & Co. Inc. - Business segments
  • Exhibit 80: Merck & Co. Inc.- Key news
  • Exhibit 81: Merck & Co. Inc. - Key offerings
  • Exhibit 82: Merck & Co. Inc. - Segment focus

• 10.11 Pfizer Inc.
  • Exhibit 83: Pfizer Inc. - Overview
  • Exhibit 84: Pfizer Inc. - Business segments
  • Exhibit 85: Pfizer Inc.- Key news
  • Exhibit 86: Pfizer Inc. - Key offerings
  • Exhibit 87: Pfizer Inc. - Segment focus

• 10.12 Sanofi SA
  • Exhibit 88: Sanofi SA - Overview
  • Exhibit 89: Sanofi SA - Business segments
  • Exhibit 90: Sanofi SA- Key news
  • Exhibit 91: Sanofi SA - Key offerings
  • Exhibit 92: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$
  • Exhibit 93: Currency conversion rates for US$

• 11.3 Research methodology
  • Exhibit 94: Research Methodology
  • Exhibit 95: Validation techniques employed for market sizing
  • Exhibit 96: Information sources

• 11.4 List of abbreviations
  • Exhibit 97: List of abbreviations